Dublin, March 27, 2018 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Global Market - Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The liquid biopsy global market is projected to reach $8,730.4 million by 2024.

The factors driving the market are raising incidence of cancer, increasing preference for blood or urine based liquid biopsy, rising number of late pregnancies, technological advancements, increasing funding, agreements and collaborations. Whereas, factor such as high cost of tests with limited reimbursements and regulatory issues are restraining the market growth.

The liquid biopsy market is divided based on biomarkers, applications, sample, end-users and geography. The biomarkers market is further segmented into circulating tumor cells (CTCs), Cell-free DNA and exosomes and other, among them Cell-free DNA commanded the largest share and circulating tumor cells are project to grow at highest CAGR from 2017 to 2024. The applications market is segmented into oncology testing, prenatal non-invasive testing and transplantation diagnostics.

The oncology testing commanded the largest revenue of in 2017 and transplantation diagnostics is expected to show highest CAGR growth. The oncology testing market is further segmented based on type of cancer into lung, breast, colorectal, ovarian, prostate, melanoma and others. The breast cancer commanded the largest share in 2017 and lung cancer is expected to grow at double digit CAGR from 2017 to 2024. In segmentation based on cancer care, the application market consists of early screening, companion diagnostics, prognosis and recurrence monitoring. The companion diagnostics commanded the largest revenue in 2017 where as recurrence monitoring is projected to grow at strong double digit CAGR from 2017 to 2024.

Technological advancements in liquid biopsy are expansion of applications beyond cancer diagnostics and monitoring to include other conditions such as cardiac health and infectious diseases and exploring of new sources for liquid biopsy such as miRNA, protein biomarkers and circulating MRNA. A paper based dip test called has been developed by scientists from Broad institute of MIT and Harvard, SHERLOCK, that make use of Cas13 CRISPR associated protein that bind to specific RNA to identify specific targets. This test is expected to detect tumor DNA in the near future.

The possibility of detection of health condition of an individual based on simple blood test has ignited imagination of scientific community and a flurry of activity has been unleashed. The absence of rigorous regulatory requirement as in case of a drug or a medical device also reduces the time to market for these tests which is attracting private investments.

Some of the recent investments are funding of $40 million to MedGenome Labs Ltd by group of investors (HDFC, Sequoia, Sofina s.a. Zodiac Capital for expansion of clinical genomic testing of NIPT, Series C funding of DiaCarta in February 2018, to Support Company's core XNA technology and expansion of diagnostic products. Biggest of them all investment of $900 million in GRAIL, Inc a spinoff of Illumina by Johnson & Johnson and Jeff Bezos of Amazon for development of ctDNA based tests.

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Take Aways
2.2 Report Description
2.3 Markets Covered
2.4 Stakeholders
2.5 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers And Opportunities
3.3.1.1 Rising Incidence Of Cancer
3.3.1.2 Increasing Preference For Blood/Urine Based Liquid Biopsy Over Invasive Tissue Biopsy Procedures
3.3.1.3 Rising Number Of Late Pregnancies Leading To High Incidence Rate Of Babies With Chromosomal Disorders
3.3.1.4 Increasing Funding For Liquid Based Test Development
3.3.1.5 Technological Advancements In Liquid Biopsy
3.3.1.6 Agreements And Collaborations
3.3.1.7 Increasing Number Of Liquid Biopsy Test Launches
3.3.2 Restraints And Threats
3.3.2.1 High Cost With Less Reimbursement Facilities
3.3.2.2 Ethical Issues Related To Genetic Testing
3.3.2.3 Lack Of Skilled Healthcare Professionals
3.3.2.4 Lack Of Standardization Of Liquid Biopsy Tests
3.3.2.5 Regulatory Issues
3.4 Regulatory Affairs
3.4.1 U.S.
3.4.2 Europe
3.4.3 China
3.4.4 India
3.4.5 Japan
3.5 Porter's Five Force Analysis
3.5.1 Threat Of New Entrants
3.5.2 Threat Of Substitutes
3.5.3 Competitive Rivalry
3.5.4 Bargaining Power Of Suppliers
3.5.5 Bargaining Power Of Buyers
3.6 Patent Trends
3.7 Market Share Analysis
3.8 Reimbursement Scenario
3.9 Clinical Trials
3.10 Technological Advancements
3.10.1 Microrna (Mirna)
3.10.2 Protein Biomarkers
3.10.3 Circulating Mrna
3.10.4 Crispr Paper Test (Sherlock)
3.11 Upcoming Tests
3.12 Research Use Only Cell-Free Dna Tests
3.13 Funding Scenario
3.14 Liquid Biopsy Company Comparison By Applications

4 Market Sizing
4.1 U.S.Liquid Biopsy Market Sizing Information
4.1.1 Oncology Testing
4.1.1.1 Early Screening
4.1.1.2 Companion Diagnostics
4.1.1.3 Prognosis Monitoring
4.1.1.4 Recurrence Monitoring
4.1.2 Non-Invasive Prenatal Screening (Nipt)
4.1.3 Transplantation Diagnostics

5 Liquid Biopsy Global Market, By Biomarker
5.1 Introduction
5.2 Circulating Tumour Cells (Ctc)
5.3 Cell-Free Dna (Cfdna)
5.4 Exosomes & Others

6 Liquid Biopsy Global Market, By Application
6.1 Introduction
6.2 Oncology Testing
6.2.1 Cancer Types
6.2.1.1 Introduction
6.2.1.2 Lung Cancer
6.2.1.3 Breast Cancer
6.2.1.4 Colorectal Cancer
6.2.1.5 Melanoma
6.2.1.6 Prostate Cancer
6.2.1.7 Ovarian Cancer
6.2.1.8 Others
6.2.2 Cancer Care
6.2.2.1 Introduction
6.2.2.2 Early Screening
6.2.2.3 Companion Diagnosis
6.2.2.4 Prognosis Monitoring
6.2.2.5 Recurrence Monitoring
6.3 Prenatal Testing
6.4 Transplantation

7 Liquid Biopsy Global Market, By Sample
7.1 Introduction
7.2 Blood
7.3 Urine And Others

8 Liquid Biopsy Global Market, By End-Users
8.1 Introduction
8.2 Hospitals
8.3 Academic & Research Institutes

9 Regional Analysis

10 Competitive Landscape
10.1 Introduction
10.2 Agreements
10.3 Collaborations/Partnerships
10.4 New Product Launches
10.5 Approvals
10.6 Acqustions
10.7 Others

11 Major Companies

  • Bgi (Bgi Diagnostics)
  • Biocept, Inc.
  • Caredx, Inc.
  • Cynvenio Biosystems, Inc
  • Eurofins Scientific Se (Lifecodexx)
  • Exact Sciences Corporation
  • Exosome Diagnostics, Inc
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Immucor
  • Laboratory Corporation Of America Holdings
  • Mdx Health
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Roche Holdings Ag

Companies Mentioned

  • Abbott Diagnostics
  • Adaptive biotechnologies
  • Admera health
  • Affinity DNA
  • Agena Bioscience, Inc
  • Agilent (Multiplicom)
  • AIOCARE Pvt Ltd (NIPTlab)
  • Ambry Genetics
  • Annoroad Gene Technology
  • Apollo Center for Fetal Medicine
  • ARUP Laboratories
  • Beijing Berry and Kang Biotechnology Co., Ltd (Berry Genom
  • BGI Diagnostics
  • Bioarray SL
  • Biocartis N.V.
  • Biocept, Inc
  • Biodesix, Inc
  • BioMarcare technologies
  • Bio-Rad Laboratories,
  • Boreal Genomics
  • Cancer Genetics, Inc
  • CareDx, Inc
  • CellMax Life
  • Chronix Biomedical
  • Circulogene theranostics
  • Cooper Genomics (Recombine)
  • Counsyl, Inc
  • Cynvenio Biosystems, Inc
  • Datar Genetics Limited
  • Diacarta, Inc
  • DiaDx
  • DNA Forensics Laboratory
  • DNA Labs India
  • Eone-Diagnomics Genome Center (EDGC)
  • Epic Sciences, Inc
  • Epicgenomics AG
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • Exosome Diagnostics, Inc
  • Foundation Medicine, Inc
  • Future health Biobank
  • GATC Biotech AG
  • GenePath Dx
  • GeneTech
  • Genetracer Biotech
  • Genome Care
  • Genomic Diagnostics
  • Genomic Health, Inc
  • Genoptix
  • Gensignia Life Sciences, Inc.
  • Guardant Health, Inc
  • Igenomix
  • Illumina, Inc
  • Immucor
  • ImpactLab Srl
  • Inivata limited
  • Integrated Diagnostics, Inc. (InDi Dx)
  • Invitae Corporation
  • LabCorp
  • Lab Genomics
  • Laboratory of Advanced Medicine (IvyGeneLabs)
  • LCM Genect Srl
  • LifeCell International Pvt. Ltd
  • Liquid biotech USA, Inc
  • MapMyGenome
  • MDx Health
  • Medgenome Labs Pvt. Ltd
  • Menarini Silicon Biosystems Inc
  • Metamark Genetics, Inc.
  • Microgenomics Srl
  • MiRXes pte Ltd
  • Molecular MD
  • Myriad Genetics,Inc
  • Natera, Inc
  • NeoGenomics Laboratories, Inc
  • NIPD Genetics Public Company Ltd
  • NxGen MDx LLC
  • Oncocyte corporation
  • OncoDNA S.A.
  • OPKO Health, Inc (Bio-reference Laboratories) (Genpath Diagnos
  • Pangaea oncology
  • Pathway genomics
  • Personal Genome Diagnostics, Inc
  • PGL Labs, LLC (Pernonalized Genomics)
  • Positive Bioscience
  • Premaitha Health, PLC
  • Progenity, Inc
  • Provista Diagnostics, Inc
  • ProXeom
  • Qiagen N.V.
  • Quest Diagnostics Incorporated
  • Resolution Biosciences, Inc
  • Roche Diagnostics
  • SAGA Diagnostics
  • Shanghai Genomatrix Medical Laboratory Co. Ltd.
  • Siemens (Neo New Oncology GmbH)
  • Sistemas Genomicos SL
  • Strand Life Sciences Pvt Ltd
  • SynapseDiagnostics
  • Synlab International
  • Sysmex Inostics GmbH
  • TAI Diagnostics
  • Trovagene, Inc
  • Vanadis diagnostics (Perkin Elmer)
  • Variantyx
  • Vermillion, Inc (Aspira Labs)
  • Victorian Clinical Genetics Services (VCGS)
  • VolitionRX Limited
  • Zer Laboratories, Ltd

For more information about this report visit https://www.researchandmarkets.com/research/rrb9jm/liquid_biopsy?w=12

CONTACT: 


CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: In Vitro Diagnostics

Ads